title: Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
abstract: Type 2 diabetes mellitus and the closely related metabolic syndrome are associated with significant risk for cardiovascular disease. Recent evidence suggests that both conditions are increasing in epidemic proportions. Dyslipidemia is characterized by increased triglyceride-rich lipoproteins; low high-density lipoprotein cholesterol; small, dense low-density lipoprotein particles; increased postprandial lipemia; and abnormal apolipoprotein A1 and B metabolism. All these lipoprotein disturbances accelerate atherosclerosis in these patients. It is likely that many patients will need combinations of lipid-modifying therapy to achieve American Diabetes Association (ADA), Adult Treatment Panel III, and American Heart Association (AHA)/American College of Cardiology (ACC) guidelines to help prevent cardiovascular disease and death.
authors.affiliation: McConnell Heart Health Center and Riverside Methodist Hospital, Columbus, Ohio 43214, USA.
authors.forename: Daryl A
authors.initials: DA
authors.lastname: Cottrell
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Marshall
authors.forename: James M
authors.initials: JM
authors.lastname: Falko
mesh_terms: D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001384:Azetidines / Q000494:pharmacology / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000503:physiopathology; D000069438:Ezetimibe; D011345:Fenofibrate / Q000494:pharmacology / Q000627:therapeutic use; D005395:Fish Oils / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000503:physiopathology; D015228:Hypertriglyceridemia / Q000097:blood / Q000503:physiopathology; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D009525:Niacin / Q000494:pharmacology / Q000627:therapeutic use; D010316:Particle Size
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D008078:Cholesterol, LDL; D005395:Fish Oils; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D009525:Niacin; D000069438:Ezetimibe; D011345:Fenofibrate